Broad Institute CRISPR: EPO Patent Revocation Lessons for Claiming Priority to Provisional Applications
D. Benjamin Borson
Borson Law Group P.C.
This article provides a brief summary of the revocation by the EPO of EP 2,771,468 (EP ‘468 patent). The EP ‘468 patent is drawn to use of CRISPR technology for gene editing in eukaryotic cells. The EP ‘468 patent named The Broad Institute, MIT, and Harvard College as Applicants. The patent was opposed by Novozymes A/S, CRISPR Therapeutics GG and others.